Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference
September 21 2021 - 5:14PM
Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage
biopharmaceutical company focused on developing transformative
medicines for the treatment of diseases of the retina and optic
nerve, today announced that Fred Guerard, PharmD, Chief Executive
Officer of Graybug Vision, will present at the 2021 Cantor Virtual
Global Healthcare Conference on Tuesday, September 28, 2021 at
11:20 a.m. ET / 8:20 a.m. PT. Dr. Guerard will provide a corporate
update, including a full analysis of the 18-month data from the
ALTISSIMO Phase 2b trial of GB-102 1mg.
A live webcast of the presentation will be available in the
Investors and Media section of the company’s website at
https://investors.graybug.vision/news-events/events-presentations,
with a replay available shortly after the live
event.
About Graybug
Graybug is a clinical-stage biopharmaceutical company focused on
developing transformative medicines for the treatment of diseases
of the retina and optic nerve. The company’s proprietary ocular
delivery technologies are designed to maintain effective drug
levels in ocular tissue for six months and potentially longer,
improving disease management, reducing healthcare burdens and
ultimately delivering better clinical outcomes. Graybug’s lead
product candidate, GB-102, a formulation of the pan-vascular
endothelial growth factor (VEGF) inhibitor, sunitinib malate
targeting a six-month or longer dosing regimen, inhibits multiple
neovascular pathways for the intravitreal treatment of retinal
diseases, including wet age-related macular degeneration. Graybug’s
other product candidates developed using its proprietary
technologies also include GB-401, an injectable sustained-release
formulation of a beta-adrenergic blocker prodrug, for primary
open-angle glaucoma, with a dosing regimen of once every six months
or longer, and GB-103, a longer-acting version of GB-102, designed
to maintain therapeutic drug levels in the retinal tissue for 12
months with a single injection. Founded in 2011 on the basis of
technology licensed from the Johns Hopkins University School of
Medicine, Graybug is headquartered in Baltimore, Maryland. For more
information, please visit www.graybug.vision.
Investor
ContactIR@graybug.vision(650) 487-2409 |
Media
Contactmedia@graybug.vision(404) 384-0067 |
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Jul 2023 to Jul 2024